Answers are grounded in this paper and cite their sources.
Despite early results of a phase 2 ustekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that ustekinumab may unmask or aggravate joint disease in selected patients. These data underscore the need for further investigation of ustekinumab's effects on psoriatic arthritis.
No takes yet. Share an insight, caveat, or question.
Stamell et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: